Laboratory of Veterinary Pharmacology, School of Veterinary Medicine, Kitasato University, Aomori, Japan.
J Vet Med Sci. 2023 Dec 19;85(12):1314-1318. doi: 10.1292/jvms.23-0306. Epub 2023 Oct 18.
Eukaryotic elongation factor 2 (eEF2) kinase (eEF2K) is a protein kinase that inactivates eEF2, a protein that mediates a peptidyl-tRNA translocation during an elongation step of protein synthesis. We have previously shown that eEF2K was involved in pathogenesis of essential and pulmonary hypertension. A484954 (7-amino-1-cyclopropyl-3-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d] pyrimidine-6-carboxamide), a selective eEF2K inhibitor, is a membrane permeable small molecule. We have previously shown that A484954 lowered blood pressure and induced diuretic effects in spontaneously hypertensive rats (SHR) due to an increase in renal blood flow. Here we aimed to reveal mechanisms underlying the diuretic effects of A484954 in SHR. A484954-induced diuresis and increase in urinary Na excretion were inhibited by N (G)-nitro-L-arginine methyl ester (L-NAME), a nitric oxide (NO) synthase inhibitor. A484954 increased mRNA expression of angiotensin type 2 receptor (AT2R) and nuclear factor-erythroid 2-related factor 2 (Nrf2). In summary, we for the first time revealed that A484954 induces diuresis in SHR at least partly via the activation of NO/Nrf2/AT2R pathway.
真核延伸因子 2(eEF2)激酶(eEF2K)是一种蛋白激酶,可使 eEF2 失活,eEF2 是一种在蛋白质合成的延伸步骤中介导肽酰-tRNA 易位的蛋白质。我们之前已经表明,eEF2K 参与了原发性和肺动脉高压的发病机制。A484954(7-氨基-1-环丙基-3-乙基-2,4-二氧代-1,2,3,4-四氢吡啶并[2,3-d]嘧啶-6-甲酰胺),一种选择性的 eEF2K 抑制剂,是一种膜通透性小分子。我们之前已经表明,A484954 通过增加肾血流量降低自发性高血压大鼠(SHR)的血压并诱导利尿作用。在这里,我们旨在揭示 A484954 在 SHR 中利尿作用的机制。N(G)-硝基-L-精氨酸甲酯(L-NAME),一种一氧化氮(NO)合酶抑制剂,抑制了 A484954 诱导的利尿作用和尿钠排泄增加。A484954 增加了血管紧张素 II 型受体(AT2R)和核因子-红细胞 2 相关因子 2(Nrf2)的 mRNA 表达。总之,我们首次揭示,A484954 通过激活 NO/Nrf2/AT2R 途径至少部分诱导 SHR 利尿。